Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/284 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME11214126
PMID: | 11214126
LR: | 20061115
CED: | 20010213
DCO: | 20010222
Autoren: | Reginster JY; Deroisy R; Rovati LC; Lee RL; Lejeune E; Bruyere O; Giacovelli G; Henrotin Y; Dacre JE; Gossett C
Titel: | Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.
Quelle: | Lancet; VOL: 357 (9252); p. 251-6 /20010127/
PM: | Print
SU: | AIM IM
Sprache: | English
CY: | England
JID: | 2985213R
ISSN: | 0140-6736
CO: | LANCAO
Institution: | Bone and Cartilage Metabolism Research Unit (WHO Collaborating Center for Public Aspects of Osteoarticular Disorders), University of Liege, Belgium. jyreginster@ulg.ac.be
DT: | Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Schlagwörter
CT: | ADMINISTRATION, ORAL; AGED; DIETARY SUPPLEMENTS/*; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLUCOSAMINE/*therapeutic use; HUMANS; KNEE JOINT/radiography; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE/*drug therapy; OSTEOARTHRITIS, KNEE/radiography; PLACEBOS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME
CTG: | APPLIKATION, ORALE; ALTE MENSCHEN; NAHRUNGSERGÄNZUNGSMITTEL/*; KRANKHEITSPROGRESSION; DOPPELBLINDMETHODE; WEIBLICH; GLUCOSAMIN/*therapeutische Anwendung; MENSCH; KNIEGELENK/Röntgenuntersuchung; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE, KNIE/*Arzneimitteltherapie; OSTEOARTHROSE, KNIE/Röntgenuntersuchung; PLAZEBOS; STATISTIK, NICHTPARAMETRISCHE; BEHANDLUNGSERGEBNIS
TE: | Placebos; Glucosamine/3416-24-8
CR: | 3416-24-8
NOTE: | Comment in: Clin J Sport Med. 2002 Mar;12(2):136; Ref.PMID: 11980439; Comment in: Lancet. 2001 Jan 27;357(9252):247-8; Ref.PMID: 11214122; Comment in: Lancet. 2001 May 19;357(9268):1617-8; Ref.PMID: 11386309; Comment in: Lancet. 2001 May 19;357(9268):1617; author reply 1618; Ref.PMID: 11386310; Comment in: Lancet. 2001 May 19;357(9268):1617; author reply 1618; Ref.PMID: 11386311; Comment in: Lancet. 2001 May 19;357(9268):1617; author reply 1618; Ref.PMID: 11386312
AB: | BACKGROUND: Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug glucosamine sulphate on the long-term progression of osteoarthritis joint structure changes and symptoms. METHODS: We did a randomised, double-blind placebo controlled trial, in which 212 patients with knee osteoarthritis were randomly assigned 1500 mg sulphate oral glucosamine or placebo once daily for 3 years. Weightbearing, anteroposterior radiographs of each knee in full extension were taken at enrolment and after 1 and 3 years. Mean joint-space width of the medial compartment of the tibiofemoral joint was assessed by digital image analysis, whereas minimum joint-space width--ie, at the narrowest point--was measured by visual inspection with a magnifying lens. Symptoms were scored by the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index. FINDINGS: The 106 patients on placebo had a progressive joint-space narrowing, with a mean joint-space loss after 3 years of -0.31 mm (95% CI -0.48 to -0.13). There was no significant joint-space loss in the 106 patients on glucosamine sulphate: -0.06 mm (-0.22 to 0.09). Similar results were reported with minimum joint-space narrowing. As assessed by WOMAC scores, symptoms worsened slightly in patients on placebo compared with the improvement observed after treatment with glucosamine sulphate. There were no differences in safety or reasons for early withdrawal between the treatment and placebo groups. INTERPRETATION: The long-term combined structure-modifying and symptom-modifying effects of gluosamine sulphate suggest that it could be a disease modifying agent in osteoarthritis.

» Volltext »
» Fenster schließen »